Fig. 1From: The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world dataSchematic representation of the pertuzumab treatment protocol. AC-DH: 2012–2015 cohort; A: doxorubicin; C: cyclophosphamide; DH: docetaxel plus trastuzumab; AC-DHP – 2015-2017 cohort; A: doxorubicin; C: cyclophosphamide; DHP - docetaxel, trastuzumab plus pertuzumabBack to article page